BioVaxys Technology (XCNQ:BIOV) Cash-to-Debt : N/A (As of Jul. 2023)

BioVaxys Technology Cash-to-Debt Chart

BioVaxys Technology Quarterly Data
	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	N/A

Competitive Comparison of BioVaxys Technology's Cash-to-Debt

For the Biotechnology subindustry, BioVaxys Technology's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioVaxys Technology's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVaxys Technology's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where BioVaxys Technology's Cash-to-Debt falls into.

BioVaxys Technology Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

BioVaxys Technology's Cash to Debt Ratio for the fiscal year that ended in Oct. 2022 is calculated as:

BioVaxys Technology had no debt ⁽¹⁾.

BioVaxys Technology's Cash to Debt Ratio for the quarter that ended in Jul. 2023 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVaxys Technology  (XCNQ:BIOV) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

BioVaxys Technology Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVaxys Technology (XCNQ:BIOV) Business Description